Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

45 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Max Ballin, M.D. 1869-1934.
Murphy FT. Murphy FT. Ann Surg. 1934 Nov;100(5):1034-5. doi: 10.1097/00000658-193411000-00026. Ann Surg. 1934. PMID: 17856405 Free PMC article. No abstract available.
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
Gordon KB, Reich K, Crowley JJ, Korman NJ, Murphy FT, Poulin Y, Spelman L, Yamauchi PS, Mendelsohn AM, Parno J, Rozzo SJ, Ellis CN. Gordon KB, et al. Among authors: murphy ft. J Dermatolog Treat. 2022 Feb;33(1):219-228. doi: 10.1080/09546634.2020.1747590. Epub 2020 Apr 30. J Dermatolog Treat. 2022. PMID: 32349565 Clinical Trial.
Hydroxychloroquine-induced inverse psoriasis.
Ullah A, Zeb H, Khakwani Z, Murphy FT. Ullah A, et al. Among authors: murphy ft. BMJ Case Rep. 2019 Feb 28;12(2):e224619. doi: 10.1136/bcr-2018-224619. BMJ Case Rep. 2019. PMID: 30824460 Free PMC article.
Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.
Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL; Childhood Myositis Heterogeneity Study Group. Kishi T, et al. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1088-1094. doi: 10.1002/acr.23113. Arthritis Care Res (Hoboken). 2017. PMID: 28129483 Free PMC article.
Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.
Smolen JS, Kay J, Doyle M, Landewé R, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Xu S, Zhou Y, Hsia EC. Smolen JS, et al. Among authors: murphy ft. Arthritis Res Ther. 2015 Jan 22;17(1):14. doi: 10.1186/s13075-015-0516-6. Arthritis Res Ther. 2015. PMID: 25627338 Free PMC article. Clinical Trial.
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group. Ritchlin C, et al. Ann Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30. Ann Rheum Dis. 2014. PMID: 24482301 Free PMC article. Clinical Trial.
45 results